Literature DB >> 25170097

Left ventricular hypertrophy with strain and aortic stenosis.

Anoop S V Shah1, Calvin W L Chin2, Vassilis Vassiliou1, S Joanna Cowell1, Mhairi Doris1, T'ng Choong Kwok1, Scott Semple1, Vipin Zamvar1, Audrey C White1, Graham McKillop1, Nicholas A Boon1, Sanjay K Prasad1, Nicholas L Mills1, David E Newby1, Marc R Dweck1.   

Abstract

BACKGROUND: ECG left ventricular hypertrophy with strain is associated with an adverse prognosis in aortic stenosis. We investigated the mechanisms and outcomes associated with ECG strain. METHODS AND
RESULTS: One hundred and two patients (age, 70 years [range, 63-75 years]; male, 66%; aortic valve area, 0.9 cm(2) [range, 0.7-1.2 cm(2)]) underwent ECG, echocardiography, and cardiovascular magnetic resonance. They made up the mechanism cohort. Myocardial fibrosis was determined with late gadolinium enhancement (replacement fibrosis) and T1 mapping (diffuse fibrosis). The relationship between ECG strain and cardiovascular magnetic resonance was then assessed in an external validation cohort (n=64). The outcome cohort was made up of 140 patients from the Scottish Aortic Stenosis and Lipid Lowering Trial Impact on Regression (SALTIRE) study and was followed up for 10.6 years (1254 patient-years). Compared with those without left ventricular hypertrophy (n=51) and left ventricular hypertrophy without ECG strain (n=30), patients with ECG strain (n=21) had more severe aortic stenosis, increased left ventricular mass index, more myocardial injury (high-sensitivity plasma cardiac troponin I concentration, 4.3 ng/L [interquartile range, 2.5-7.3 ng/L] versus 7.3 ng/L [interquartile range, 3.2-20.8 ng/L] versus 18.6 ng/L [interquartile range, 9.0-45.2 ng/L], respectively; P<0.001) and increased diffuse fibrosis (extracellular volume fraction, 27.4±2.2% versus 27.2±2.9% versus 30.9±1.9%, respectively; P<0.001). All patients with ECG strain had midwall late gadolinium enhancement (positive and negative predictive values of 100% and 86%, respectively). Indeed, late gadolinium enhancement was independently associated with ECG strain (odds ratio, 1.73; 95% confidence interval, 1.08-2.77; P=0.02), a finding confirmed in the validation cohort. In the outcome cohort, ECG strain was an independent predictor of aortic valve replacement or cardiovascular death (hazard ratio, 2.67; 95% confidence interval, 1.35-5.27; P<0.01).
CONCLUSION: ECG strain is a specific marker of midwall myocardial fibrosis and predicts adverse clinical outcomes in aortic stenosis.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  aortic valve stenosis; fibrosis; hypertrophy, left ventricular; troponin I

Mesh:

Substances:

Year:  2014        PMID: 25170097     DOI: 10.1161/CIRCULATIONAHA.114.011085

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  42 in total

1.  Clinical value of regression of electrocardiographic left ventricular hypertrophy after aortic valve replacement.

Authors:  Sayuri Yamabe; Yoshihiro Dohi; Akifumi Higashi; Hiroki Kinoshita; Yoshiharu Sada; Takayuki Hidaka; Satoshi Kurisu; Nobuo Shiode; Yasuki Kihara
Journal:  Heart Vessels       Date:  2015-11-03       Impact factor: 2.037

2.  Evaluation of Aortic Blood Flow and Wall Shear Stress in Aortic Stenosis and Its Association With Left Ventricular Remodeling.

Authors:  Florian von Knobelsdorff-Brenkenhoff; Achudhan Karunaharamoorthy; Ralf Felix Trauzeddel; Alex J Barker; Edyta Blaszczyk; Michael Markl; Jeanette Schulz-Menger
Journal:  Circ Cardiovasc Imaging       Date:  2016-03       Impact factor: 7.792

3.  The Romhilt-Estes electrocardiographic score predicts sudden cardiac arrest independent of left ventricular mass and ejection fraction.

Authors:  Navid Darouian; Aapo L Aro; Kumar Narayanan; Audrey Uy-Evanado; Carmen Rusinaru; Kyndaron Reinier; Karen Gunson; Jonathan Jui; Sumeet S Chugh
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-01-03       Impact factor: 1.468

4.  Electrocardiographic Impact of Myocardial Diffuse Fibrosis and Scar: MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Yuko Y Inoue; Bharath Ambale-Venkatesh; Nathan Mewton; Gustavo J Volpe; Yoshiaki Ohyama; Ravi K Sharma; Colin O Wu; Chia-Ying Liu; David A Bluemke; Elsayed Z Soliman; João A C Lima; Hiroshi Ashikaga
Journal:  Radiology       Date:  2016-10-13       Impact factor: 11.105

Review 5.  Clinical applications of multiparametric CMR in left ventricular hypertrophy.

Authors:  Sabrina Nordin; Luke Dancy; James C Moon; Daniel M Sado
Journal:  Int J Cardiovasc Imaging       Date:  2018-03-03       Impact factor: 2.357

6.  High expression of microRNA-208 is associated with cardiac hypertrophy via the negative regulation of the sex-determining region Y-box 6 protein.

Authors:  Xintao Huang; Zhiheng Li; Baoqiang Bai; Xiaohong Li; Zhongyuan Li
Journal:  Exp Ther Med       Date:  2015-07-17       Impact factor: 2.447

Review 7.  The role of cardiovascular magnetic resonance in the assessment of severe aortic stenosis and in post-procedural evaluation following transcatheter aortic valve implantation and surgical aortic valve replacement.

Authors:  Tarique Al Musa; Sven Plein; John P Greenwood
Journal:  Quant Imaging Med Surg       Date:  2016-06

8.  Prognostic value of T1 mapping and extracellular volume fraction in cardiovascular disease: a systematic review and meta-analysis.

Authors:  Baiyan Zhuang; Arlene Sirajuddin; Shuli Wang; Andrew Arai; Shihua Zhao; Minjie Lu
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 9.  Risk Stratification in Patients With Aortic Stenosis Using Novel Imaging Approaches.

Authors:  Calvin W L Chin; Tania A Pawade; David E Newby; Marc R Dweck
Journal:  Circ Cardiovasc Imaging       Date:  2015-08       Impact factor: 7.792

10.  Sensitive troponin assay and the classification of myocardial infarction.

Authors:  Anoop S V Shah; David A McAllister; Rosamund Mills; Kuan Ken Lee; Antonia M D Churchhouse; Kathryn M Fleming; Elizabeth Layden; Atul Anand; Omar Fersia; Nikhil V Joshi; Simon Walker; Allan S Jaffe; Keith A A Fox; David E Newby; Nicholas L Mills
Journal:  Am J Med       Date:  2014-11-28       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.